The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
BackgroundJAK inhibitors treat various autoimmune diseases, but an updated systematic review in treating alopecia areata is currently lacking.ObjectiveEvaluate the specific efficacy and safety of JAK inhibitors in alopecia areata by systematic review and meta-analysis.MethodsEligible studies in PubM...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1195858/full |
| _version_ | 1797813577840590848 |
|---|---|
| author | Mei-qi Mao Yu-xin Ding Jing Jing Zhen-wei Tang Yu-jie Miao Xiao-shuang Yang Yu-hong Chen Sheng-zhao Chen Xian-jie Wu Zhong-fa Lu |
| author_facet | Mei-qi Mao Yu-xin Ding Jing Jing Zhen-wei Tang Yu-jie Miao Xiao-shuang Yang Yu-hong Chen Sheng-zhao Chen Xian-jie Wu Zhong-fa Lu |
| author_sort | Mei-qi Mao |
| collection | DOAJ |
| description | BackgroundJAK inhibitors treat various autoimmune diseases, but an updated systematic review in treating alopecia areata is currently lacking.ObjectiveEvaluate the specific efficacy and safety of JAK inhibitors in alopecia areata by systematic review and meta-analysis.MethodsEligible studies in PubMed, Embase, Web of Science, and Clinical Trials up to May 30, 2022, were searched. We enrolled in randomized controlled trials and observational studies of applying JAK inhibitors in alopecia areata.Results6 randomized controlled trials with 1455 patients exhibited SALT50 (odd ratio [OR], 5.08; 95% confidence interval [CI], 3.49-7.38), SALT90 (OR, 7.40; 95% CI, 4.34-12.67) and change in SALT score (weighted mean difference [WSD], 5.55; 95% CI, 2.60-8.50) compared to the placebo. The proportion of 26 observational studies with 563 patients of SALT5 was 0.71(95% CI, 0.65-0.78), SALT50 was 0.54(95% CI 0.46-0.63), SALT90 was 0.33(95% CI, 0.24-0.42), and SALT score (WSD, -2.18; 95% CI, -3.12 to -1.23) compared with baseline. Any adverse effects occurred in 921 of 1508 patients; a total of 30 patients discontinued the trial owing to adverse reactions.LimitationsFew randomized controlled trials met the inclusion criteria and insufficiency of eligible data.ConclusionJAK inhibitors are effective in alopecia areata, although associated with an increased risk. |
| first_indexed | 2024-03-13T07:54:50Z |
| format | Article |
| id | doaj.art-2426f21af5524fefb9f5fb1fb194761c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T07:54:50Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2426f21af5524fefb9f5fb1fb194761c2023-06-02T05:52:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-06-011410.3389/fimmu.2023.11958581195858The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patientsMei-qi MaoYu-xin DingJing JingZhen-wei TangYu-jie MiaoXiao-shuang YangYu-hong ChenSheng-zhao ChenXian-jie WuZhong-fa LuBackgroundJAK inhibitors treat various autoimmune diseases, but an updated systematic review in treating alopecia areata is currently lacking.ObjectiveEvaluate the specific efficacy and safety of JAK inhibitors in alopecia areata by systematic review and meta-analysis.MethodsEligible studies in PubMed, Embase, Web of Science, and Clinical Trials up to May 30, 2022, were searched. We enrolled in randomized controlled trials and observational studies of applying JAK inhibitors in alopecia areata.Results6 randomized controlled trials with 1455 patients exhibited SALT50 (odd ratio [OR], 5.08; 95% confidence interval [CI], 3.49-7.38), SALT90 (OR, 7.40; 95% CI, 4.34-12.67) and change in SALT score (weighted mean difference [WSD], 5.55; 95% CI, 2.60-8.50) compared to the placebo. The proportion of 26 observational studies with 563 patients of SALT5 was 0.71(95% CI, 0.65-0.78), SALT50 was 0.54(95% CI 0.46-0.63), SALT90 was 0.33(95% CI, 0.24-0.42), and SALT score (WSD, -2.18; 95% CI, -3.12 to -1.23) compared with baseline. Any adverse effects occurred in 921 of 1508 patients; a total of 30 patients discontinued the trial owing to adverse reactions.LimitationsFew randomized controlled trials met the inclusion criteria and insufficiency of eligible data.ConclusionJAK inhibitors are effective in alopecia areata, although associated with an increased risk.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1195858/fullJAK/STAT (janus kinase/signal transducer and activator of transcription)JAK inhibitorsalopecia areataimmune-mediated diseasesmeta-analysis |
| spellingShingle | Mei-qi Mao Yu-xin Ding Jing Jing Zhen-wei Tang Yu-jie Miao Xiao-shuang Yang Yu-hong Chen Sheng-zhao Chen Xian-jie Wu Zhong-fa Lu The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients Frontiers in Immunology JAK/STAT (janus kinase/signal transducer and activator of transcription) JAK inhibitors alopecia areata immune-mediated diseases meta-analysis |
| title | The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients |
| title_full | The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients |
| title_fullStr | The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients |
| title_full_unstemmed | The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients |
| title_short | The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients |
| title_sort | evaluation of jak inhibitors on effect and safety in alopecia areata a systematic review and meta analysis of 2018 patients |
| topic | JAK/STAT (janus kinase/signal transducer and activator of transcription) JAK inhibitors alopecia areata immune-mediated diseases meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1195858/full |
| work_keys_str_mv | AT meiqimao theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT yuxinding theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT jingjing theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT zhenweitang theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT yujiemiao theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT xiaoshuangyang theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT yuhongchen theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT shengzhaochen theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT xianjiewu theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT zhongfalu theevaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT meiqimao evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT yuxinding evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT jingjing evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT zhenweitang evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT yujiemiao evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT xiaoshuangyang evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT yuhongchen evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT shengzhaochen evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT xianjiewu evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients AT zhongfalu evaluationofjakinhibitorsoneffectandsafetyinalopeciaareataasystematicreviewandmetaanalysisof2018patients |